Pharmafile Logo

Genesis Research Group survey discovers how payers are responding to Maximum Fair Prices (MFPs) under the Inflation Reduction Act

December 6, 2024 |  

To better understand how MFPs might impact payer utilization management strategies, rebate negotiations, and business approaches, Genesis Research Group employed their RPR stakeholder engagement platform and vetted stakeholder network to survey 12 payer organizations.

IRA payer survey results

How are payers responding to Maximum Fair Prices (MFPs) under the Inflation Reduction Act? Explore our findings.

To better understand how MFPs might impact payer utilization management strategies, rebate negotiations, and business approaches, we employed our RPR stakeholder engagement platform and vetted stakeholder network to survey 12 payer organizations. This included national and regional Managed Care Organizations (MCOs), Pharmacy Directors (PDs), Integrated Delivery Networks (IDNs), and Pharmacy Benefit Managers (PBMs), representing a total of 96 million MCO/IDN lives and 115 million PBM lives.

Our findings reveal critical insights into how payers are adapting to the recent release of MFPs for key pharmaceutical products under the IRA. For example:

💡 Payers view the MFPs for the diabetes and cardiovascular products most favorably and plan to leverage them in upcoming commercial rebate negotiations. However, payers see unmet needs for further discounts for the immunology and oncology products.

💡 Payers are divided on preferring MFP over non-MFP products due to the potential for non-MFP products to offer more aggressive rebates or better clinical benefits.

View the graphic above for further details.

This is just the first glimpse into a larger narrative. Follow us on LinkedIn to view Part Two of our findings and stay tuned for our interim report within the coming weeks. This report will offer further detail as to how MFPs could reshape both payer strategies and the healthcare market.

You can find out more about our RPR stakeholder engagement platform and global network of 3500+ vetted stakeholders online or contact solutions@genesisrg.com if you have questions or would like to request a copy of the report in advance.

Follow us on LinkedIn>>

This content was provided by Genesis Research Group

Company Details

 Latest Content from  Genesis Research Group 

World EPA Congress 2024: ‘Shining the light on vaccine market access’ by Genesis Research Group

A presentation with Katrin Nather, PhD, Associate Director, and Tijana Ignjatovic, Executive Director, Genesis Research Group. Contact solutions@genesisrg.com or visit www.genesisrg.com. With more and more innovative vaccines and immunization strategies...

Fit-for-purpose matchmaking webinar: a data selection and RWE approach for both regulatory and HTA audiences

This webinar reviews considerations for the design and data selection for RWE studies, including external control arm studies, to meet regulatory and HTA needs. Regulators and agencies responsible for market...

Genesis Research Group RWD / HTA / regulatory / ECA webinar on 15 Feb: reserve your place!

On 15 February 2024, Carole Longson and Allie Sosinsky of Genesis Research Group, a leading global provider of tech-enabled real-world evidence, market access, and HEOR solutions, will present a webinar...

Genesis Research Insights & Evidence webinar 20 Oct: Reserve your place!

Join Priti Jhingran of Genesis Research and Tijana Ignjatovic of Market Access Transformation (MAT) for their webinar 'Accelerating the Generation of Payer Insights and Evidence Across the Product Lifecycle to...

Leading pharmaceutical executive Jennifer Fillman joins evidence-based solution provider Genesis Research as Chief Financial Officer

International health economics and outcomes research (HEOR) and real-world evidence (RWE) organization Genesis Research has announced the appointment of Jennifer Fillman as its new Chief Financial Officer. Prior to joining...